A SYSTEMS BIOLOGY APPROACH TO OCULAR INFLAMMATIO

Completed

Conditions: ocular inflammation
uveitis
10021877

Registration Number: NL-OMON55622

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Trial ended prematurely

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 630

Inclusion Criteria

Patients aged under 96 years old diagnosed with ocular inflammation:
- uveitis; anterior uveitis, intermediate uveitis, panuveitis, scleritis and
posterior uveitis
- inflammatory corneal disease (keratokonus or Fuchs endothelial corneal
dystrophy)
- inflammatory orbital disease and orbital lymphoma
- Age-related macular degeneration
- Retinal dystrophy
- Multifocal choroidal retinitis
- Strabismus

Exclusion Criteria

- Patients with acquired immune deficiencies will not be eligible for
participation.
- Patients who do not speak or understand the Dutch language adequately will
also be excluded from participation in this study
- Current effective use of systemic immunomodulatory agents (antimetabolites),
biologicals or cyclosporine.
-IV corticosteroids in the last 14 days for inclusion
-Age >=96 years

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>the networks acquisition of high throughput analyses of distinct layers (e.g.<br /><br>mRNA, microRNA, methylation status, proteome) and various cellular subsets<br /><br>(e.g. B cells, T cells, dendritic cells, NK cells)</p><br>

Secondary Outcome Measures